2-Amino-5-Bromoisonicotinic Acid for Kinase Inhibitor Synthesis
Reactivity Comparison Between CAS 1000339-23-0 and CAS 52833-94-0 for Kinase Inhibitor Synthesis
In the development of targeted kinase inhibitors, the selection of the appropriate pyridine carboxylic acid derivative is critical for establishing the correct structure-activity relationship (SAR). CAS 1000339-23-0, known chemically as 2-Amino-5-bromoisonicotinic acid, offers distinct reactivity profiles compared to isomers such as CAS 52833-94-0. The positioning of the bromine atom at the 5-position relative to the amino group at the 2-position facilitates specific palladium-catalyzed cross-coupling reactions essential for building complex kinase scaffolds.
From a process chemistry perspective, the nucleophilicity of the amino group in CAS 1000339-23-0 is modulated by the electron-withdrawing carboxylic acid and the bromine substituent. This balance is crucial when performing amidation or heterocycle formation steps common in pharma building block utilization. During our internal process validation, we observed that trace impurities in lower-grade materials can lead to catalyst poisoning during Suzuki-Miyaura couplings. Furthermore, operators should note that solubility in polar aprotic solvents like DMF can shift significantly at sub-zero temperatures, affecting filtration rates during workup if the reaction mixture is cooled too rapidly. For detailed specifications on this specific intermediate, review our 2-Amino-5-bromoisonicotinic acid high purity pharma intermediate page.
Pharmaceutical Grade Purity Specifications: HPLC ≥99.5% and Related Substances Profile
Ensuring high purity is non-negotiable when synthesizing active pharmaceutical ingredients (APIs). For kinase inhibitor pathways, related substances must be tightly controlled to prevent downstream purification failures. Our standard pharmaceutical grade material targets an HPLC purity of ≥99.5%. However, purity alone does not guarantee performance; the profile of related substances is equally important.
Specific attention is paid to isomeric brominated impurities and unreacted starting materials from the 2-amino-5-bromopyridine-4-carboxylic acid synthesis route. These impurities can co-elute or react similarly during subsequent steps, complicating isolation. We utilize rigorous chromatographic methods to quantify these traces. Below is a comparison of typical technical parameters between standard and pharmaceutical grades.
| Parameter | Technical Grade | Pharmaceutical Grade | Test Method |
|---|---|---|---|
| Purity (HPLC Area %) | ≥98.0% | ≥99.5% | HPLC |
| Single Impurity | ≤1.0% | ≤0.15% | HPLC |
| Total Impurities | ≤2.0% | ≤0.5% | HPLC |
| Appearance | Off-white to Yellow | Light Yellow Powder | Visual |
GMP Compliance via COA Parameters: Heavy Metals, Residual Solvents, and Loss on Drying
Compliance with GMP expectations requires comprehensive documentation via the Certificate of Analysis (COA). Beyond organic purity, inorganic impurities and residual solvents pose significant risks to patient safety and reaction efficiency. Heavy metals, particularly palladium or nickel residues from upstream synthesis, must be minimized to avoid interfering with downstream catalytic steps.
Residual solvents are classified according to ICH guidelines. Class 2 solvents are limited to strict ppm thresholds, while Class 3 solvents are monitored for general safety. Loss on Drying (LOD) is a critical parameter for this pyridine carboxylic acid derivative, as excessive moisture can hinder coupling reactions requiring anhydrous conditions. Please refer to the batch-specific COA for exact numerical values regarding heavy metals and residual solvents, as these vary based on the production run and purification cycles employed.
Bulk Packaging Solutions for Stability: Nitrogen-Flushed Drums and Moisture Barrier Liners
Physical stability during transit is as important as chemical stability. 2-Amino-5-bromoisonicotinic acid is susceptible to moisture absorption, which can alter its physical flow properties and introduce water into sensitive reaction vessels. To mitigate this, we utilize nitrogen-flushed drums equipped with high-density polyethylene moisture barrier liners.
Standard packaging options include 25kg fiber drums or IBC totes for larger volumes. The nitrogen flush displaces oxygen, reducing the risk of oxidative degradation of the amino group during storage. It is important to note that while we ensure robust physical packaging to maintain integrity during shipping, regulatory compliance regarding environmental certifications is the responsibility of the importer based on local jurisdiction. Our focus remains on delivering the material in the exact chemical state it left the production line.
Validating CAS 1000339-23-0 for Scale-Up: Batch Consistency and Reactivity Performance Data
Transitioning from laboratory scale to commercial production requires consistent batch-to-batch performance. Variations in crystal morphology or particle size distribution can impact dissolution rates in large-scale reactors. At NINGBO INNO PHARMCHEM CO.,LTD., we monitor batch consistency through strict internal controls.
During scale-up validation, we track reactivity performance data, focusing on conversion rates and yield consistency in model kinase inhibitor reactions. A non-standard parameter we monitor is the thermal degradation threshold during prolonged heating in solvent. Exceeding specific temperature limits during the dissolution phase can lead to decarboxylation, generating impurities that are difficult to remove later. By maintaining strict thermal profiles during handling, we ensure the custom synthesis pathways utilizing this intermediate remain robust and reproducible.
Frequently Asked Questions
What is the standard Minimum Order Quantity (MOQ) for this intermediate?
The standard MOQ typically starts at 25kg, aligned with our drum packaging specifications. Smaller quantities for R&D sampling may be available upon request.
Can you provide a Certificate of Analysis (COA) before shipment?
Yes, a batch-specific COA including HPLC chromatograms and test results for heavy metals and residual solvents is provided with every shipment.
Do you offer custom synthesis services for modified derivatives?
Yes, our R&D team supports custom synthesis for structurally related analogues based on specific project requirements and feasibility studies.
What is the typical lead time for bulk orders?
Lead times vary based on current inventory and production schedules. Please contact our sales team for a confirmed timeline based on your required quantity.
Sourcing and Technical Support
Reliable sourcing of critical intermediates is fundamental to accelerating drug discovery timelines. Our team provides comprehensive technical support to assist with integration into your existing synthesis workflows. We prioritize supply chain stability and transparent communication to ensure your projects proceed without interruption. Partner with a verified manufacturer. Connect with our procurement specialists to lock in your supply agreements.